ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

BMK Benchmark Holdings Plc

45.00
-0.50 (-1.10%)
03 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Benchmark Holdings Plc LSE:BMK London Ordinary Share GB00BGHPT808 ORD 0.1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.50 -1.10% 45.00 44.10 45.90 43.20 43.00 43.00 126,760 16:35:11
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 169.74M -23.15M -0.0313 -13.80 319.4M

Benchmark Holdings PLC Genetics Breakthrough in Tilapia

11/07/2019 7:00am

RNS Non-Regulatory


TIDMBMK

Benchmark Holdings PLC

11 July 2019

Benchmark Holdings plc

("Benchmark" or the "Company")

Genetics breakthrough to increase resistance to Streptococcus iniae in tilapia

Addresses one of the biggest challenges in the world's second most farmed species

Benchmark, the aquaculture health, nutrition and genetics business, is pleased to announce a significant discovery to increase genetic resistance to Streptococcus iniae infections in tiliapia, one of the biggest challenges in the aquaculture industry.

Benchmark's team of geneticists have identified a significant quantitative trait locus (QTL), a small section of DNA, which is linked to increased levels of resistance to Streptococcus iniae. The Company has made a patent application in respect of this discovery.

The identified QTL will be used for commercial production of tilapia fry marking the first time that a significant QTL for disease resistance is used in commercial breeding of tilapia.

Tilapia is the world's second most farmed fish with 6.3 million tonnes of production in 2018 (estimated commercial value of GBP6.6 bn) and is growing at c. 5% CAGR (2017 - 2022) according to the United Nations Food and Agriculture Organisation.

Following this discovery, Benchmark's tilapia broodstock are selected both for improved resistance to Streptococcus agalactiae using genomic selection, and to Streptococcus iniae using the identified QTL in marker-assisted selection.

Malcolm Pye, CEO Benchmark commented:

"This is a major step forward for the tilapia industry. It is the result of Benchmark's many years of investment and commitment to bringing state-of-the-art breeding technology to this important farmed species.

"We believe that this breakthrough will allow the industry to expand production of this cost effective, high-quality, protein source to meet global demand for protein. We have seen first hand how devastating Streptococcus is to the industry and with the introduction of this new technology we can drive improvements in sustainability and profitability for our customers."

- ENDS -

Enquiries

 
 Benchmark Holdings plc                    Tel: 020 3915 1236 
 Malcolm Pye, CEO 
 Mark Plampin, CFO 
 Ivonne Cantu, Investor Relations 
 
 
 Numis (Broker and NOMAD)                  Tel: 020 7260 1000 
 James Black, Freddie Barnfield, Freddie 
  Naylor-Leyland 
 
 MHP Communications                        Tel: 020 3128 8226 
 

Katie Hunt / Reg Hoare / Alistair de Kare-Silver benchmark@mphc.com

- ENDS -

About Benchmark

Benchmark's mission is to enable food producers to improve their sustainability and profitability.

We bring together biology and technology, to develop innovative products which improve yield, quality and animal health and welfare for our customers. We do this by improving the genetic make-up, health and nutrition of their stock - from broodstock and hatchery through to nursery and grow out.

Benchmark has a broad portfolio of products and solutions, including salmon eggs, live feed (artemia), sea lice treatments, training and data management tools. Find out more at www.benchmarkplc.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

NRARMMFTMBIBBBL

(END) Dow Jones Newswires

July 11, 2019 02:00 ET (06:00 GMT)

1 Year Benchmark Chart

1 Year Benchmark Chart

1 Month Benchmark Chart

1 Month Benchmark Chart

Your Recent History

Delayed Upgrade Clock